Sai Life Sciences has announced the scheduling of its Q4FY26 earnings conference call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call is set to discuss the company's audited financial results for the quarter and year ended March 31, 2026. The intimation was filed on May 11, 2026, and signed by Company Secretary & Compliance Officer Runa Karan.

Conference Call Details

The earnings call will be held on Friday, May 15, 2026, from 4:00 PM to 5:00 PM IST. The session will open with a brief management discussion on earnings performance, followed by an interactive Question & Answer segment. The key details of the call are summarised below:

Participants may also use the pre-registration facility to dial in directly without waiting for an operator, accessible via the registration URL provided by the company.

Management Representation

The following senior management members will represent Sai Life Sciences on the call:

• Mr. Krishna Kanumuri — Managing Director & Chief Executive Officer
• Mr. Siva Chittor — Director and Chief Financial Officer

About Sai Life Sciences

Sai Life Sciences is one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO), partnering with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, the company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. Investors and analysts seeking further information may contact the company at Investorrelation@sailife.com or visit www.sailife.com .

Sai Life Sciences Limited has informed the stock exchanges about receipt of a Goods and Services Tax (GST) order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi. The order was passed on 29 April 2026 at 11:32 AM under Section 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka Goods and Services Tax Act, 2017.

Details of the GST Order

The order raises a demand concerning alleged excess availment of input tax credit in GSTR-3B than available in GSTR-2A for the financial year 2021-22. The tax authority has specified the following amounts:

Company's Response

According to the disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Life Sciences Limited stated that based on its assessment, an appeal will be filed against the order. The company expressed hope for a favourable outcome at the Tribunal level and indicated that it does not reasonably expect the said order to have any material financial impact on its operations.

The disclosure was signed by Runa Karan, Company Secretary & Compliance Officer, and submitted to both the National Stock Exchange of India Limited and BSE Limited on 30 April 2026.